ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ドリペネム

Doripenem

HCID 73303
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
148016-81-3
標準SMILES
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12
InChIKey
AVAACINZEOAHHE-VFZPANTDSA-N
分子式
C15H24N4O6S2
平均分子量
420.5 g/mol
単同位体質量
420.11372685

概要

Doripenem is a member of carbapenems.

名称と識別子

優先名称
Doripenem
IUPAC
(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
現地名
ドリペネム
英語名
Doripenem
分子式
C15H24N4O6S2
分子量
420.5

名称と別名

Doripenem148016-81-3DoribaxFinibaxS-4661doripenemum(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acidDTXSID2046678BHV525JOBHDTXCID00266781-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-{[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl}-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
名称をさらに表示
ドリペネム(4R,5S,6S)-6-[(1R)-1-ヒドロキシエチル]-4-メチル-7-オキソ-3-{[(3S,5S)-5-[(スルファモイルアミノ)メチル]ピロリジン-3-イル]スルファニル}-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸(4R,5S,6S)-6-[(1R)-1-ヒドロキシエチル]-4-メチル-7-オキソ-3-[[(3S,5S)-5-(スルファモイルアミノメチル)ピロリジン-3-イル]チオ]-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸(4R,5S,6S)-3-[[(3S)-5β-(スルファモイルアミノメチル)ピロリジン-3β-イル]チオ]-4α-メチル-6β-[(R)-1-ヒドロキシエチル]-7-オキソ-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸(4R,5β)-3-[[(3S)-5β-[(スルファモイルアミノ)メチル]ピロリジン-3β-イル]チオ]-4α-メチル-6β-[(1R)-1-ヒドロキシエチル]-7-オキソ-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸

物性

構造計算による物性

XLogP
-3.4
極性表面積
196 Ų
水素結合供与体数
5
水素結合受容体数
10
回転可能結合数
7
重原子数
27
形式電荷
0
複雑度
780

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Listed in ZINC15

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antibacterial Agents; Carbapenems

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

物理化学的性質

融点
186 °C · >186°C dec.
沸点
694.8 · 694.8±65.0 °C(Predicted)
比重(密度)
1.59 · 1.59±0.1 g/cm3(Predicted)
貯蔵温度
-20 °C · Sealed in dry,Store in freezer, under -20°C
溶解性
20 mg/ml、pBS · 水では不明、DMSO では 20 mg/ml、pBS では 3 mg/ml
外見
個体
酸解離定数(Pka)
4.27 · 4.27±0.60(Predicted)
色
ホワイトからライトベージュ
安定性
吸湿性
CAS データベース
148016 · 148016-81-3
化学的性質 · 1 件

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Hepatotoxicity · 1 件

Mild, transient, asymptomatic elevations in serum aminotransferase levels occur in 1% to 5% of patients receiving parenteral doripenem for 5 to 14 days. These abnormalities are usually self-limited and asymptomatic and rarely above 5 times the upper limit of normal. In the limited period that it has been available, no cases of hepatitis with jaundice have been reported. Nevertheless, several instances of cholestatic jaundice arising during or shortly after therapy have been reported with other carbapenems. The latency to onset has been within 1 to 3 weeks and the pattern of enzyme elevations is usually cholestatic. Immunoallergic features can occur, but autoantibodies are rare. The course is usually self-limiting, but at least one case of vanishing bile duct syndrome related to a carbapenem has been reported. Doripenem and other carbapenems have not been linked to cases of acute liver failure.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Doripenem

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

化学と産業

薬理情報

ATC Code · 2 件

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein Binding8.1%
PharmacodynamicsSimilar to other beta-lactam antimicrobial agents, the time that unbound plasma concentration of doripenem exceeds the MIC (T>MIC) of the infecting organism has been shown to best correlate with efficacy in animal models of infection.
Mechanism of Action · 1 件

Doripenem is a broad-spectrum carbapenem antibiotic with activity against many gram-positive and gram-negative aerobic bacteria, as well as a variety of anaerobes. Like other beta-lactam antibiotics, doripenem's bactericidal mechanism of action is mostly due to cell death after inhibition of bacterial enzymes called penicillin-bindng proteins (PBPs), which are responsible for peptidoglycan cross-linking during the synthesis of the bacterial cell wall. Carbapenems mainly have high affinity for PBPs 1a, 1b, 2 and 3. Inhibition of each PBP usually results in a different inactivating mechanism. Inhibition of PBPs 1a and 1b results in fast bacterial killing through the formation of spheroplasts, inhibition of PBP 2 results in rod-shaped bacteria to become spherical, and inhibition of PBP 3 results in filamentous-shaped organisms. The PBPs preferentially bound by different carbapenems depend on the organism. In E.coli and P.aeruginosa, doripenem binds to PBP 2, which is involved in the maintenance of cell shape, as well as to PBPs 3 and 4. Doripenem has a 1-beta-methyl side chain, which allows it to be relatively resistant to dehydropeptidase, as well as a trans-alpha-1-hydroxyethyl group at position 6 which provides beta-lactamase resistance. Like other carbapenems, doripenem is different from most beta-lactams due to its stability against hydrolysis by most beta-lactamases, including penicillinases, cephalosporinases, ESBL, and Amp-C producing enterobacteriaceae.

Biological Half-Life1 hour, in healthy non-elderly adults.
Metabolism/MetabolitesMetabolism of doripenem is via dehydropeptidase-I (also called dipeptidase-1) into a microbiologically inactive ring-opened metabolite, doripenem-M1. Doripenem does not appear to be a substrate of the hepatic CYP450 enzymes.

関連反応

1 件
反応記録を作成
HRID 2094649 の反応式
HRID 2094649反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
(+)-(4R,5S,6S)-6-((1R)-1-ヒドロキシエチル)-4-メチル-7-オキソ-3-[(3S,5S)-5-(スルファモイルアミノメチル)ピロリジン-3-イルスルファニル]-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸
DoripeneM Monohydrate
CS-841
Donipenem
Donipenam
duonipeinan
Doripenem D5
Doripenem API
Doripenem (S 4661)
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-(4R,5S,6S)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)sulfanyl)-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid(4R,5S,6S)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-3-((3S,5S)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)sulfanyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-({(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl}sulfanyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acidRefChem:56365J01DH04S4661S 4661

データベース識別子

CAS
148016-81-3
PubChem CID
73303
DTXSID
DTXSID2046678
ChEMBL
CHEMBL491571
ChEBI
CHEBI:135928
UNII
BHV525JOBH
Nikkaji
J1.864.558K

化学的特性Doripenem white to somewhat yellowish crystalline powder which is moderately soluble in water, slightly soluble in methanol, and virtually insoluble in ethanol. Doripenem is also solution in N,N-dimethylformamide. The chemical configuration of doripenem’s has 6 asymmetrical carbon atoms (6 stereocenters) and is most commonly supplied as one pure isomer. In terms of doripenem for injection, the crystallized powered drug can form a monohydrate when mixed with water.

FDA Pharmacological Classification · 5 件

BHV525JOBH

DORIPENEM

Chemical Structure [CS] - Carbapenems

Established Pharmacologic Class [EPC] - Penem Antibacterial

Doripenem is a Penem Antibacterial.

MeSH Pharmacological ClassificationSubstances that inhibit the growth or reproduction of BACTERIA.
Absorption, Distribution and Excretion · 4 件

Doripenem is administered intravenously as an infusion. There was no accumulation of doripenem following mulitiple infusions of either 500mg or 1g administered every 8 hours for 7-10 days in subjects with normal renal function.

Doripenem is primarily eliminated unchanged by the kidneys and undergoes glomerular filtration and active tubular secretion. A mean of 71% and 15% of the dose was recovered in urine as unchanged drug and the ring-opened metabolite, respectively, within 48 hours of 500 mg dose in healthy adults. Following the administration of a single 500 mg dose of radiolabeled doripenem to healthy adults, less than 1% of the total radioactivity was recovered in feces after one week.

The average Vd is 16.8 L (8.09-55.5 L) at steady-state in healthy subjects. Doripenem penetrates into many tissues and fluids, including potential sites of approved indication infections.

10.3 L/hour.

用途と製造

UsesUse (kg; approx.) in Germany (2009): >10
応用分野 · 3 件

用途カルバペネム系抗生物質抗菌活性

説明Doripenem monohydrate is an ultra-broad-spectrum injectable β-lactam antibiotic and belongs to the subgroup of carbapenems. It was introduced by Shionogi Co. of Japan under the brand name Finibax in 2005 and is being marketed outside Japan by Johnson & Johnson. Doripenem act by decreases the process of cell wall growth, which eventually leads to elimination of the infectious cell bacteria together. It is used for treatment of bacterial respiratory and urinary tract infections. Doripenem is a 1β-methyl carbapenem derivative, and it is the fourth analog to be marketed in this series following the launch of meropenem, biapenem, and ertapenem in previous years. The introduction of a 1β-methyl group to the carbapenem skeleton enhances metabolic stability to renal dehydropeptidase-1 (DHP-1) and leads to improved antibacterial potency.

使用Doripenem hydrate is used to treat complicated urinary infection including Pyelonephritis caused by E.coli. Doripenem hydrate is promoted in the United States as DORIBAX(R). This drug is synthesized from p-nitrobenzyl-protected enolphosphate 2b and N-(p-nitrobenzyloxycarbonyl)-protected aminomethylpyrrolidine.

上流・下流製品情報

上流原料

(4R,5S,6S)-3-[[(3S,5S)-5-[[(Aminosulfonyl)amino]methyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (4-nitrophenyl)methyl ester